rantes response (ccr5 Search Results


mycobacterium tuberculosis lehmann and neumann  (ATCC)
98
ATCC mycobacterium tuberculosis lehmann and neumann
Mycobacterium Tuberculosis Lehmann And Neumann, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mycobacterium tuberculosis lehmann and neumann/product/ATCC
Average 98 stars, based on 1 article reviews
mycobacterium tuberculosis lehmann and neumann - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
skge004  (Bio-Techne corporation)
98
Bio-Techne corporation skge004
Skge004, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/skge004/product/Bio-Techne corporation
Average 98 stars, based on 1 article reviews
skge004 - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
rantes response (ccr5  (DiscoverX corporation)
90
DiscoverX corporation rantes response (ccr5
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Rantes Response (Ccr5, supplied by DiscoverX corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rantes response (ccr5/product/DiscoverX corporation
Average 90 stars, based on 1 article reviews
rantes response (ccr5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
huv-ec-c  (ATCC)
99
ATCC huv-ec-c
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Huv Ec C, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/huv-ec-c/product/ATCC
Average 99 stars, based on 1 article reviews
huv-ec-c - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
mspi  (New England Biolabs)
96
New England Biolabs mspi
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Mspi, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mspi/product/New England Biolabs
Average 96 stars, based on 1 article reviews
mspi - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pkge004b  (Bio-Techne corporation)
98
Bio-Techne corporation pkge004b
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Pkge004b, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pkge004b/product/Bio-Techne corporation
Average 98 stars, based on 1 article reviews
pkge004b - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
prostaglandin e2 parameter assay kit  (Bio-Techne corporation)
97
Bio-Techne corporation prostaglandin e2 parameter assay kit
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Prostaglandin E2 Parameter Assay Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostaglandin e2 parameter assay kit/product/Bio-Techne corporation
Average 97 stars, based on 1 article reviews
prostaglandin e2 parameter assay kit - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
cd3e, mouse(145-2c11)  (Biotium)
99
Biotium cd3e, mouse(145-2c11)
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Cd3e, Mouse(145 2c11), supplied by Biotium, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd3e, mouse(145-2c11)/product/Biotium
Average 99 stars, based on 1 article reviews
cd3e, mouse(145-2c11) - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
ecori  (New England Biolabs)
99
New England Biolabs ecori
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Ecori, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ecori/product/New England Biolabs
Average 99 stars, based on 1 article reviews
ecori - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
pkge004  (Bio-Techne corporation)
98
Bio-Techne corporation pkge004
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Pkge004, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pkge004/product/Bio-Techne corporation
Average 98 stars, based on 1 article reviews
pkge004 - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
mycobacterium tuberculosis subsp.tuberculosis  (ATCC)
99
ATCC mycobacterium tuberculosis subsp.tuberculosis
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Mycobacterium Tuberculosis Subsp.Tuberculosis, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mycobacterium tuberculosis subsp.tuberculosis/product/ATCC
Average 99 stars, based on 1 article reviews
mycobacterium tuberculosis subsp.tuberculosis - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
mmp9 antibody / matrix metalloproteinase-9  (NSJ Bioreagents)
99
NSJ Bioreagents mmp9 antibody / matrix metalloproteinase-9
Screening of 35K-Fc mutants by <t>CCR5</t> DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by <t>RANTES</t> as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.
Mmp9 Antibody / Matrix Metalloproteinase 9, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mmp9 antibody / matrix metalloproteinase-9/product/NSJ Bioreagents
Average 99 stars, based on 1 article reviews
mmp9 antibody / matrix metalloproteinase-9 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


Screening of 35K-Fc mutants by CCR5 DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by RANTES as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.

Journal: Molecular pharmacology

Article Title: Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade

doi: 10.1124/mol.111.071985

Figure Lengend Snippet: Screening of 35K-Fc mutants by CCR5 DiscoveRx assay. A, dose-response curve showing recruitment of β-arrestin in response to CCR5 activation by RANTES as measured by PathHunter eXpress assay (DiscoveRx). B, RANTES (5 nM) was preincubated for 2 h with the indicated concentration of WT 35K-Fc (●) or MR-Fc (○) and then added to the assay. A and B show mean ± S.E.M. of two technical replicates and are representative of three independent experiments. C, RANTES (5 nM) was preincubated with the indicated 35K-Fc mutant (fixed dose, 15 nM) and then added to PathHunter eXpress CCR5 transfected cells and β-arrestin recruitment measured according to manufacturer’s instructions. Data are shown as the percentage of the response to RANTES alone and are the mean of two independent experiments ± S.E.M., each with two technical replicates for two batches of protein (i.e., four wells per mutant per experiment). Statistical analysis performed by one-way ANOVA and Dunnett’s multiple comparison post test. ***, p < 0.001 relative to WT 35K-Fc.

Article Snippet: Data for all mutants are summarized in . table ft1 table-wrap mode="anchored" t5 caption a7 Mutant RANTES Response (CCR5 DiscoveRx) IC 50 Overall Rank CHO-CCR2 xCelligence CCR5 DiscoveRx CCR2 DiscoveRx CCR7 DiscoveRx MΦ xCelligence % nM WT 35.1 90.0 6.6 ± 0.9 (3) 13.9 ± 1 (3) 12.2 ± 0.4 (2) 3 ± 0.8 (3) 3 Y80A 95.6 >1000 10 R89A 15.1 20.6 3.7 ± 1.7 (4) * 3.1 ± 0.4 (2) *** 4.1 ± 0.1 (2) ** 1 ± 0.4 (3) * 1 D141A 74.3 139.0 4 D141L 80.6 >750 8 D141R 79.4 >700 6 E143A 71.7 5 E143K 93.9 >5000 N.D. (3) N.D. (2) N.D. (3) 11 E143R 92.5 11 V185A 26.5 50.0 2 Y217A 66.5 >5000 7 Y217N 67.5 >1400 6 MR-Fc 91.2 >1400 N.D. (3) N.D. (2) N.D. (3) 9 Open in a separate window N.D., IC 50 could not be determined (i.e., a curve could not be fitted).

Techniques: Activation Assay, Concentration Assay, Mutagenesis, Transfection

Summary of data for 35K-Fc mutants Values are presented as mean ± S.D. Column 2 summarizes data shown in Fig. 3C and indicates the response to 5 nM RANTES (set as 100%) in a CCR5 DiscoveRx assay after preincubation of 5 nM RANTES with 15 nM 35K-Fc. Column 3 gives the IC 50 (mean of two technical replicates) for the indicated 35K-Fc mutant in a single xCELLigence ECIS screening assay with CCR2-transfected CHO cells responding to 10 nM MCP-1. Columns 4 to 7 show the IC 50 from the number of independent experiments as indicated in parentheses. Statistical analysis was performed by unpaired t test. Columns 4 and 5 summarize the data shown in Fig. 4 . Column 6 gives the IC 50 for the indicated 35K-Fc mutant in a DiscoveRx assay with CCR7-transfected CHO cells responding to 10 nM MIP-3 β (CCL19). Column 7 summarizes the data shown in . The final column indicates the overall rank of the mutants (1, most potent chemokine blockade; 11, least potent).

Journal: Molecular pharmacology

Article Title: Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade

doi: 10.1124/mol.111.071985

Figure Lengend Snippet: Summary of data for 35K-Fc mutants Values are presented as mean ± S.D. Column 2 summarizes data shown in Fig. 3C and indicates the response to 5 nM RANTES (set as 100%) in a CCR5 DiscoveRx assay after preincubation of 5 nM RANTES with 15 nM 35K-Fc. Column 3 gives the IC 50 (mean of two technical replicates) for the indicated 35K-Fc mutant in a single xCELLigence ECIS screening assay with CCR2-transfected CHO cells responding to 10 nM MCP-1. Columns 4 to 7 show the IC 50 from the number of independent experiments as indicated in parentheses. Statistical analysis was performed by unpaired t test. Columns 4 and 5 summarize the data shown in Fig. 4 . Column 6 gives the IC 50 for the indicated 35K-Fc mutant in a DiscoveRx assay with CCR7-transfected CHO cells responding to 10 nM MIP-3 β (CCL19). Column 7 summarizes the data shown in . The final column indicates the overall rank of the mutants (1, most potent chemokine blockade; 11, least potent).

Article Snippet: Data for all mutants are summarized in . table ft1 table-wrap mode="anchored" t5 caption a7 Mutant RANTES Response (CCR5 DiscoveRx) IC 50 Overall Rank CHO-CCR2 xCelligence CCR5 DiscoveRx CCR2 DiscoveRx CCR7 DiscoveRx MΦ xCelligence % nM WT 35.1 90.0 6.6 ± 0.9 (3) 13.9 ± 1 (3) 12.2 ± 0.4 (2) 3 ± 0.8 (3) 3 Y80A 95.6 >1000 10 R89A 15.1 20.6 3.7 ± 1.7 (4) * 3.1 ± 0.4 (2) *** 4.1 ± 0.1 (2) ** 1 ± 0.4 (3) * 1 D141A 74.3 139.0 4 D141L 80.6 >750 8 D141R 79.4 >700 6 E143A 71.7 5 E143K 93.9 >5000 N.D. (3) N.D. (2) N.D. (3) 11 E143R 92.5 11 V185A 26.5 50.0 2 Y217A 66.5 >5000 7 Y217N 67.5 >1400 6 MR-Fc 91.2 >1400 N.D. (3) N.D. (2) N.D. (3) 9 Open in a separate window N.D., IC 50 could not be determined (i.e., a curve could not be fitted).

Techniques: Mutagenesis, Screening Assay

Comparison of 35K-Fc WT, R89A, and E143K proteins by DiscoveRx β arrestin assay. A, dose-response curve of beta arrestin recruitment in response to CCR2 activation by MCP-1. B, MCP-1 (3 nM) was preincubated with the indicated concentration of WT 35K-Fc (●), R89A 35K-Fc (■) or E143K 35K-Fc (○) for 2 h then applied to the DiscoveRx assay. C and D, as for A and B, using CCR5 DiscoveRx cells and RANTES as the chemokine ligand. E and F, as for A and B, using CXCR2 DiscoveRx cells and IL-8 as the chemokine ligand. A and B show the mean ± S.E.M. of two technical replicates and are representative of two to three independent experiments. C and D show the mean ± S.E.M. of two technical replicates and are representative of three to four independent experiments. E and F show the mean ± S.E.M. of two technical replicates and are representative of two independent experiments.

Journal: Molecular pharmacology

Article Title: Site-Directed Mutagenesis of the CC Chemokine Binding Protein 35K-Fc Reveals Residues Essential for Activity and Mutations That Increase the Potency of CC Chemokine Blockade

doi: 10.1124/mol.111.071985

Figure Lengend Snippet: Comparison of 35K-Fc WT, R89A, and E143K proteins by DiscoveRx β arrestin assay. A, dose-response curve of beta arrestin recruitment in response to CCR2 activation by MCP-1. B, MCP-1 (3 nM) was preincubated with the indicated concentration of WT 35K-Fc (●), R89A 35K-Fc (■) or E143K 35K-Fc (○) for 2 h then applied to the DiscoveRx assay. C and D, as for A and B, using CCR5 DiscoveRx cells and RANTES as the chemokine ligand. E and F, as for A and B, using CXCR2 DiscoveRx cells and IL-8 as the chemokine ligand. A and B show the mean ± S.E.M. of two technical replicates and are representative of two to three independent experiments. C and D show the mean ± S.E.M. of two technical replicates and are representative of three to four independent experiments. E and F show the mean ± S.E.M. of two technical replicates and are representative of two independent experiments.

Article Snippet: Data for all mutants are summarized in . table ft1 table-wrap mode="anchored" t5 caption a7 Mutant RANTES Response (CCR5 DiscoveRx) IC 50 Overall Rank CHO-CCR2 xCelligence CCR5 DiscoveRx CCR2 DiscoveRx CCR7 DiscoveRx MΦ xCelligence % nM WT 35.1 90.0 6.6 ± 0.9 (3) 13.9 ± 1 (3) 12.2 ± 0.4 (2) 3 ± 0.8 (3) 3 Y80A 95.6 >1000 10 R89A 15.1 20.6 3.7 ± 1.7 (4) * 3.1 ± 0.4 (2) *** 4.1 ± 0.1 (2) ** 1 ± 0.4 (3) * 1 D141A 74.3 139.0 4 D141L 80.6 >750 8 D141R 79.4 >700 6 E143A 71.7 5 E143K 93.9 >5000 N.D. (3) N.D. (2) N.D. (3) 11 E143R 92.5 11 V185A 26.5 50.0 2 Y217A 66.5 >5000 7 Y217N 67.5 >1400 6 MR-Fc 91.2 >1400 N.D. (3) N.D. (2) N.D. (3) 9 Open in a separate window N.D., IC 50 could not be determined (i.e., a curve could not be fitted).

Techniques: Beta-Arrestin Assay, Activation Assay, Concentration Assay